ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov.

85,013 comparisons

Most participants first33,758 with no events in either group come last2,961 to 2,980 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
Absorb BVS vs XIENCE: Number of Participants Experienced Cardiac Death/All MI133 of 1,219

118 of 1,241

1.4 points

-1.0 to 3.8

2,460NCT02173379

Absorb IV Randomized Controlled Trial

Absorb BVS vs XIENCE: Number of Participants With All Coronary Revascularization157 of 1,219

113 of 1,241

3.8 points

1.3 to 6.3

2,460NCT02173379

Absorb IV Randomized Controlled Trial

Absorb BVS vs XIENCE: Number of Participants Experienced Death/All MI/All Revascularization (DMR)241 of 1,219

198 of 1,241

3.8 points

0.8 to 6.8

2,460NCT02173379

Absorb IV Randomized Controlled Trial

Absorb BVS vs XIENCE: Number of Participants Experienced Cardiac Death/All MI/ID-TLR (MACE)183 of 1,219

152 of 1,241

2.8 points

0.1 to 5.5

2,460NCT02173379

Absorb IV Randomized Controlled Trial

Absorb BVS vs XIENCE: Number of Participants With Ischemia Driven TLR (ID-TLR)87 of 1,219

50 of 1,241

3.1 points

1.3 to 5.0

2,460NCT02173379

Absorb IV Randomized Controlled Trial

Absorb BVS vs XIENCE: Number of Participants With Target Vessel Revascularization (TVR)67 of 1,219

49 of 1,241

1.5 points

-0.1 to 3.3

2,460NCT02173379

Absorb IV Randomized Controlled Trial

Absorb BVS vs XIENCE: Number of Participants With Target Vessel Myocardial Infarction (TV-MI)112 of 1,219

86 of 1,241

2.3 points

0.1 to 4.4

2,460NCT02173379

Absorb IV Randomized Controlled Trial

Absorb BVS vs XIENCE: Number of Participants Experienced Cardiac Death/All MI/ID-TLR/ID-TVR, Non TL (TVF)211 of 1,219

171 of 1,241

3.5 points

0.7 to 6.4

2,460NCT02173379

Absorb IV Randomized Controlled Trial

Absorb BVS vs XIENCE: Number of Participants With Target Lesion Revascularization (TLR)90 of 1,219

50 of 1,241

3.4 points

1.5 to 5.2

2,460NCT02173379

Absorb IV Randomized Controlled Trial

Absorb BVS vs XIENCE: Number of Participants With ID-TVR Excluding TLR65 of 1,219

48 of 1,241

1.5 points

-0.2 to 3.2

2,460NCT02173379

Absorb IV Randomized Controlled Trial

Absorb BVS vs XIENCE: Number of Participants Experienced All Death/All MI150 of 1,219

132 of 1,241

1.7 points

-0.9 to 4.2

2,460NCT02173379

Absorb IV Randomized Controlled Trial

Absorb BVS vs XIENCE: Number of Death (Cardiac, Vascular, Non-cardiovascular)39 of 1,219

32 of 1,241

0.6 points

-0.7 to 2.0

2,460NCT02173379

Absorb IV Randomized Controlled Trial

Exposed Cohort vs Unexposed Cohort: Number of Subjects With Pre-specified Neonate-related Outcomes, Resulting in Neonates Small for Their Gestational Age69 of 1,199

62 of 1,259

0.8 points

-1.0 to 2.6

2,458NCT02757950

A Post-marketing, Observational, Retrospective Study to Assess the Safety of RefortrixTM (Tdap) When Administered During Pregnancy in a Maternal Immunization Program in Brazil.

Exposed Cohort vs Unexposed Cohort: Number of Subjects Reporting Gestational Diabetes10 of 1,199

22 of 1,259

-0.9 points

-1.9 to -0.0

2,458NCT02757950

A Post-marketing, Observational, Retrospective Study to Assess the Safety of RefortrixTM (Tdap) When Administered During Pregnancy in a Maternal Immunization Program in Brazil.

Exposed Cohort vs Unexposed Cohort: Number of Subjects With Pre-specified Neonate-related Outcomes Resulting in Preterm Birth64 of 1,199

121 of 1,259

-4.3 points

-6.4 to -2.2

2,458NCT02757950

A Post-marketing, Observational, Retrospective Study to Assess the Safety of RefortrixTM (Tdap) When Administered During Pregnancy in a Maternal Immunization Program in Brazil.

Exposed Cohort vs Unexposed Cohort: Number of Subjects Reporting Pregnancy Hemorrhage4 of 1,199

19 of 1,259

-1.2 points

-2.0 to -0.4

2,458NCT02757950

A Post-marketing, Observational, Retrospective Study to Assess the Safety of RefortrixTM (Tdap) When Administered During Pregnancy in a Maternal Immunization Program in Brazil.

Exposed Cohort vs Unexposed Cohort: Number of Subjects Reporting Cases of Congenital Anomalies in the Neonates3 of 1,199

22 of 1,259

-1.5 points

-2.4 to -0.7

2,458NCT02757950

A Post-marketing, Observational, Retrospective Study to Assess the Safety of RefortrixTM (Tdap) When Administered During Pregnancy in a Maternal Immunization Program in Brazil.

Group 1 vs Group 2: Impact of Remote Patient Navigation Services529 of 1,330

284 of 1,127

14.6 points

10.9 to 18.2

2,457NCT04514341

Implementing a Multilevel Intervention to Accelerate Colorectal Cancer Screening and Follow-up

TDF/FTC vs Placebo: Grade 2, 3, or 4 Clinical Adverse Events157 of 1,226

162 of 1,230

-0.4 points

-3.0 to 2.3

2,456NCT00458393

Emtricitabine/Tenofovir Disoproxil Fumarate for HIV Prevention in Men

TDF/FTC vs Placebo: serious adverse events92 of 1,226

94 of 1,230

-0.1 points

-2.2 to 2.0

2,456NCT00458393

Emtricitabine/Tenofovir Disoproxil Fumarate for HIV Prevention in Men

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Code

Show the call in
curl "https://conductscience.org/api/comparisons/v1?page=149"

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=149

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT02173379-13c67d1e",
        "title": "Absorb BVS vs XIENCE: Number of Participants Experienced Cardiac Death/All MI",
        "summary": "133 of 1219 against 118 of 1241; risk difference 1.4 points, 95% interval -1.0 to 3.8; NCT02173379, Absorb IV Randomized Controlled Trial",
        "record": "/library/comparisons/NCT02173379-13c67d1e",
        "nct_id": "NCT02173379",
        "kind": "outcome",
        "participants": 2460,
        "risk_difference": {
          "value": 0.014021215260127215,
          "lower": -0.009954433206044246,
          "upper": 0.03808762275203276
        },
        "group_1": "133 of 1,219",
        "group_2": "118 of 1,241",
        "difference": "1.4 points",
        "interval": "-1.0 to 3.8",
        "trial_title": "Absorb IV Randomized Controlled Trial"
      },
      {
        "id": "NCT02173379-1d464c00",
        "title": "Absorb BVS vs XIENCE: Number of Participants With All Coronary Revascularization",
        "summary": "157 of 1219 against 113 of 1241; risk difference 3.8 points, 95% interval 1.3 to 6.3; NCT02173379, Absorb IV Randomized Controlled Trial",
        "record": "/library/comparisons/NCT02173379-1d464c00",
        "nct_id": "NCT02173379",
        "kind": "outcome",
        "participants": 2460,
        "risk_difference": {
          "value": 0.03773849319695738,
          "lower": 0.013032528033280918,
          "upper": 0.0625820918554061
        },
        "group_1": "157 of 1,219",
        "group_2": "113 of 1,241",
        "difference": "3.8 points",
        "interval": "1.3 to 6.3",
        "trial_title": "Absorb IV Randomized Controlled Trial"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "No license stated"
    }
  ],
  "next": "/api/comparisons/v1?page=150",
  "request_id": "HsMULMIzEC6ISshV"
}

Ask about these results. The first 10 go in the prompt.

About this data
Holds
85,013 comparisons
From ClinicalTrials.gov. Counted 10 Nov 2026.
Release
23 Mar 2026
trial-comparisons-2026-03-23-0.1.0
Checked
20 of 20 review comparisons traced to ClinicalTrials.gov, and all 510,078 numbers calculated again apart from the builder agree
Access
Open
No account. 60 calls a minute from one address.

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

Opens sequences.conductscience.org

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?